Spectrum Pharma's (SPPI) Drop Seen as 'Overreaction' at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Appleās first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
- Brazil's Bolsonaro, Lula spar in first debate as personal attacks fly
- Yorkville Ives: 'GameStop Is Becoming the Hobby's Intake Network'
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Micron Technology stock drops on China chip news and labor dispute
- Truist Financial to sell $7.7B LightStream loan portfolio to Carlyle
Spectrum Pharma (SPPI) Receives CRL from FDA Regarding EVOMELA
October 23, 2015 7:35 AM EDTSpectrum Pharma (NASDAQ: SPPI) announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA). A Complete Response Letter is a communication from the FDA that informs companies that an application cannot be approved in... More



